Head-to-head evidence
BMS-986435 vs Mavacamten
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac myosin (inhibitor) · full Heart Failure pipeline
BMS-986435
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06122779 (registry estimate)
Mavacamten · Camzyos
Marketed by Bristol-Myers Squibb
NCT04766892 · Phase 2 · completed
The study enrolled 30 participants in a single mavacamten arm with no randomization, blinding, or placebo/active comparator. Its primary outcomes were descriptive safety measures and biomarker changes rather than a hard clinical endpoint, so the reported findings cannot provide a controlled estimate of mavacamten’s benefit.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMS-986435's landscape · Mavacamten's landscape